Literature DB >> 20709027

IFN-γ activated JAK1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and low IL-10 production.

Michael Conzelmann1, Andreas H Wagner, Anke Hildebrandt, Elena Rodionova, Michael Hess, Annika Zota, Thomas Giese, Christine S Falk, Anthony D Ho, Peter Dreger, Markus Hecker, Thomas Luft.   

Abstract

CD40Ligand (CD40L) represents a strong endogenous danger signal associated with chronic inflammatory disease. CD40L induces activation of antigen-presenting cells (APCs) such as DCs, monocytes, B-cells and endothelial cells. However, CD40 activation alone, whilst inducing IL-10 production, is insufficient to induce interleukin (IL)-12p70 release in human APCs suggesting that additional cytokine signals (e.g. GM-CSF, IL-4 or IFN-γ) are required for the induction of a pro-inflammatory cytokine profile. We demonstrate that IFN-γ-induced Janus kinase 1 (JAK1) enhances CD40-induced IL-12p70 release whilst simultaneously inhibiting IL-10 synthesis, resulting in a pro-inflammatory phenotype of CD40L-activated dendritic cells (DCs). JAK2 mediated enhancing effects on IL-12p70 but did not inhibit IL-10 release, whereas Tyk2 mediated inhibitory effects on IL-12p70 release in this system. The mechanism by which complementary IFN-γ/JAK activities affect IL-12p70 production involves STAT1 activation and de novo induction of interferon-responsive factors (IRF)-1 and IRF-8. Simultaneously, JAK1 was unique in inhibiting IL-10 synthesis via STAT1 and IRF-8 with both transcription factors binding to the IL-10 promoter. We demonstrate that CD40- and JAK/STAT/IRF-signalling pathways are strictly complementary for the induction of a pro-inflammatory cytokine profile in human APCs. This suggests that a number of CD40 effects in chronic inflammatory diseases might be weakened by targeting JAK/STAT.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709027     DOI: 10.1016/j.bcp.2010.07.040

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Suppression of antigen-specific CD4+ T cell activation by SRA/CD204 through reducing the immunostimulatory capability of antigen-presenting cell.

Authors:  Huanfa Yi; Daming Zuo; Xiaofei Yu; Fanlei Hu; Masoud H Manjili; Zhengliang Chen; John R Subjeck; Xiang-Yang Wang
Journal:  J Mol Med (Berl)       Date:  2011-11-15       Impact factor: 4.599

2.  Leukotriene C(4) prevents the complete maturation of murine dendritic cells and modifies interleukin-12/interleukin-23 balance.

Authors:  Carolina Alvarez; María M Amaral; Cecilia Langellotti; Mónica Vermeulen
Journal:  Immunology       Date:  2011-10       Impact factor: 7.397

Review 3.  IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.

Authors:  Ramesh B Batchu; Oksana V Gruzdyn; Bala K Kolli; Rajesh Dachepalli; Prem S Umar; Sameer K Rai; Namrata Singh; Pavan S Tavva; Donald W Weaver; Scott A Gruber
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Arterial wall stress controls NFAT5 activity in vascular smooth muscle cells.

Authors:  Clemens Scherer; Larissa Pfisterer; Andreas H Wagner; Maren Hödebeck; Marco Cattaruzza; Markus Hecker; Thomas Korff
Journal:  J Am Heart Assoc       Date:  2014-03-10       Impact factor: 5.501

5.  Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis.

Authors:  Hai-Mei Zhao; Rong Xu; Xiao-Ying Huang; Shao-Min Cheng; Min-Fang Huang; Hai-Yang Yue; Xin Wang; Yong Zou; Ai-Ping Lu; Duan-Yong Liu
Journal:  Front Pharmacol       Date:  2016-11-25       Impact factor: 5.810

6.  Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling.

Authors:  Claudia Penafuerte; Matthew Feldhammer; John R Mills; Valerie Vinette; Kelly A Pike; Anita Hall; Eva Migon; Gerard Karsenty; Jerry Pelletier; George Zogopoulos; Michel L Tremblay
Journal:  Oncoimmunology       Date:  2017-04-28       Impact factor: 8.110

Review 7.  TYK2 in Immune Responses and Treatment of Psoriasis.

Authors:  Lin Shang; Jiali Cao; Siqi Zhao; Jingya Zhang; Yanling He
Journal:  J Inflamm Res       Date:  2022-09-16

8.  Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway.

Authors:  Wen-hua Liu; Jing-jin Liu; Jian Wu; Lu-lu Zhang; Fang Liu; Li Yin; Mao-mao Zhang; Bo Yu
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.